Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Cash from Financing Activities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Cash from Financing Activities for 12 consecutive years, with -$62000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities changed N/A to -$62000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $23.0 million, a 15.6% increase, with the full-year FY2024 number at $34.0 million, changed N/A from a year prior.
  • Cash from Financing Activities was -$62000.0 for Q3 2025 at Traws Pharma, down from $3.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $35.6 million in Q1 2021 to a low of -$62000.0 in Q3 2025.
  • A 3-year average of $9.8 million and a median of $1.6 million in 2025 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 633.77% in 2021; the steepest drop was 112.54% in 2021.
  • Traws Pharma's Cash from Financing Activities stood at -$35000.0 in 2021, then surged by 57177.14% to $20.0 million in 2024, then plummeted by 100.31% to -$62000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Cash from Financing Activities are -$62000.0 (Q3 2025), $3.1 million (Q2 2025), and $13000.0 (Q1 2025).